Emergent BioSolutions Inc.

NYSE:EBS

Biotechnology

Healthcare
$5.50 -2.58%

-$0.21 today

Market cap
$282.78M
Beta
2.33
P/E (TTM)
-47.9
EPS (TTM)
-$0.17
52W Low $5.62High $14.06

Volume 0.82M

Average 0.78M

EBS Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Emergent BioSolutions Inc.NYSE: EBS

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses declines year over year

Q1 FY2026 other income / expenses of $2.9M fell 93.4% year over year, ahead of the -280.1% change in trailing-twelve-month other income / expenses.

Context

  • Other income / expenses amounted to 3.7% of revenue in FY2025, up 0.4 pp from a year earlier.
  • Other income / expenses grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -93.4% holds above the trailing-twelve-month pace of -280.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.9M+108.5% QoQ
Last fiscal yearDec 2025
-$27.4M+19.9% YoY
LTMMar 2026
-$67.7M-280.1% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-93.4%——
1 year+19.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(27.4M) USD
Year-over-year change
+19.9%

Other Income / Expenses vs competitors

How EBS compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -280.1% is the lowest of 11, against a peer median of +4.2%.
  • Other income / expenses amounts to 10.0% of revenue for EBS, versus a peer median of 6.7%.
EBS Competitors
Other Income / Expenses for EBS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PRTAProthena Corporation plcLTM Mar 2026$20.28M USD-10.8%—35.0%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$16.66M USD+19.9%+94.7%—
SIGASIGA Technologies, Inc.LTM Mar 2026$6.29M USD+7.9%+67.2%6.7%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$3.76M USD+136.9%——
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026-$2.61M USD+55.1%—0.9%
SNDLSNDL Inc.LTM Mar 2026-CA$5.06M CAD-0.5%—0.5%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026-$6.74M USD-1.5%—1.3%
CMPSCOMPASS Pathways plcLTM Mar 2026-$12.01M USD-122.6%——
AQSTAquestive Therapeutics, Inc.LTM Mar 2026-$13.02M USD+0.4%—25.9%
EBSEmergent BioSolutions Inc.LTM Mar 2026-$67.7M USD-280.1%—10.0%
ESPREsperion Therapeutics, Inc.LTM Mar 2026-$81.37M USD+28.2%—19.5%
Peer median (excluding EBS) —+4.2%+81.0%6.7%

Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.77B1.12B1.05B1.04B742.9M
Cost of Revenue980.4M644.5M689.3M668.2M392.3M
Gross Profit793.2M473M360M375.4M350.6M
Gross Margin44.7%42.3%34.3%36.0%47.2%
Research & Development235.2M188.3M111.4M70.7M53.8M
Selling, General & Admin348.7M339.5M356.7M298.7M186.6M
Operating Expenses451.8M643M1.09B484.1M240.4M
Depreciation & Amortization118.2M125M121.1M105.6M98.3M
EBITDA504.2M15.7M(47M)53.4M240.4M
EBITDA Margin28.4%1.4%-4.5%5.1%32.4%
Operating Income341.4M(170M)(726.4M)(108.7M)110.2M
Operating Margin19.2%-15.2%-69.2%-10.4%14.8%
Interest Income00000
Interest Expense34.5M37.3M87.9M71M59.3M
Other Income / Expenses(38.2M)(49M)(4.8M)(34.2M)(27.4M)
Income Before Tax303.2M(219M)(731.2M)(142.9M)82.8M
Pre-Tax Margin17.1%-19.6%-69.7%-13.7%11.1%
Income Tax Expense83.7M(7.4M)29.3M47.7M30.2M
Net Income219.5M(211.6M)(760.5M)(190.6M)52.6M
Net Margin12.4%-18.9%-72.5%-18.3%7.1%
EPS (Basic)4.10(4.22)(14.85)(3.60)0.98
EPS (Diluted)4.06(4.22)(14.85)(3.60)0.93
Weighted Avg Shares53.5M50.1M51.2M53M53.5M
Weighted Avg Shares (Diluted)54.1M50.1M51.2M53M56.7M

Emergent BioSolutions Inc.

NYSE:EBS

Intrinsic Alpha fair value

Locked

Current Price

$5.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.